Author

Reema Mody 1

1 Takeda Pharmaceuticals International, Inc.,Deerfield,United States

A MULTINATIONAL STUDY TO DETERMINE INDICATORS OF SUBOPTIMAL THERAPY AMONG ULCERATIVE COLITIS PATIENTS TREATED WITH TUMOR NECROSIS FACTOR ANTAGONISTS

James Lindsay, Javier Gisbert, Reema Mody, Laurent Peyrin-Biroulet, Alessandro Armuzzi, Bernd Bokemeyer, Geoffrey C. Nguyen, Jean Siebenaler, Örjan Åkerborg, Michael Smyth

EVALUATION OF PATIENT-REPORTED OUTCOMES FROM THE CROHN’S DISEASE ACTIVITY INDEX TO DEFINE REMISSION IN THE GEMINI 2 STUDY

William Sandborn, Severine Vermeire, Bruce E. Sands, Brian G. Feagan, Michael Shetzline, Jing Xu, Reema Mody, Asit Parikh, Brihad Abhyankar

INDICATORS OF SUBOPTIMAL THERAPY AMONG CROHN’S DISEASE PATIENTS TREATED WITH TUMOR NECROSIS FACTOR ANTAGONISTS: RESULTS FROM A MULTINATIONAL STUDY

Alessandro Armuzzi, James Lindsay, Reema Mody, Bernd Bokemeyer, Javier Gisbert, Laurent Peyrin-Biroulet, Geoffrey C. Nguyen, Jean Siebenaler, Örjan Åkerborg, Michael Smyth

Item 1 - 3 / 3
1